George W. Sledge Jr., MD, Stanford Cancer Center

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis

Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma

Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD